Skip to main content
Premium Trial:

Request an Annual Quote

Expedeon MagniPhi & QualiPhi DNA Polymerases

Expedeon has launched two high-fidelity polymerases, MagniPhi DNA Polymerase and QualiPhi DNA Polymerase. Expedeon offers the products in both 25- and 100-reaction kits, which contain DNA polymerases and their associated reaction buffers. The firm said MagniPhi — a wild-type form of the Phi29 DNA polymerase — is ideal for isothermal DNA amplification. According to Expedeon, MagniPhi's fidelity of synthesis produces up to 100 times fewer errors than Taq polymerase, while the amplification reaction yields more whole-genome amplification compared to normal PCR-based WGA techniques.

Expedeon's QualiPhi — a chimeric form of the Phi29 DNA Polymerase — has been engineered for enhanced sensitivity and efficiency while preserving the high processivity of the wild type Phi29. According to the firm, the polymerase's higher sensitivity allows improved amplification of DNA from low to high input concentrations and higher yields than the wild-type polymerase.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.